News | March 10, 2008

Magnesium-Rich Foods Ward Off Stroke in Smokers

March 11, 2008 - Diets rich magnesium, found in whole grains and vegetables, could help reduce stroke risk in smokers, researchers Susanna Larsson and colleagues at the Karolinska Institute in Stockholm, Sweden, reported.

Their study of 26,000 male smokers in Finland found that those whose diets were high in magnesium had a significantly lower risk of one type of stroke.

While the mechanism is not clear, it may be that magnesium helps reduce high blood pressure, which can lead to stroke if untreated.

Researchers said the stroke finding was an offshoot of a study whose main purpose was to look at possible lung cancer therapies.

Cigarette smoking is strongly linked to stroke and it is the leading cause of heart disease and cancer.

The study of 26,556 Finnish men followed for more than 13 years found that those who consumed an average of 589 milligrams of magnesium each day in their diets had a 15 percent lower risk for cerebral infarction - a stroke that occurs when blood flow to the brain is blocked - than those who consumed less magnesium.

The effect was stronger for men younger than 60 and the study also found that calcium, potassium and sodium intake were not associated with risk for any type of stroke, the researchers reported in the Archives of Internal Medicine.

They said it remains to be seen if taking magnesium dietary supplements would produce the same result.

"In addition to lowering blood pressure, magnesium may influence cholesterol concentrations or the body's use of insulin to turn glucose into energy. Either of these mechanisms would affect the risk for cerebral infarction but not hemorrhage (the cause of other types of strokes)," Larsson's team wrote.

Besides whole grains, foods high in magnesium are black beans, broccoli, halibut, peanuts, oysters, rockfish and spinach.

Source: Reuters

For more information: www.reuters.com/article/healthNews


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now